Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma-Reference-Cited by-同舟云学术

Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma

Published:2018-01-22 Issue:6 Volume:24 Page:1296-1304
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Huang Jing,Xu Binghe,Mo Hongnan,Zhang Weilong,Chen Xuelian,Wu Dawei,Qu Dong,Wang Xingyuan,Lan Bo,Yang Beibei,Wang Pei,Zhang Hongtu,Yang Qing,Jiao Yuchen

Funder

National Key Basic Research Program of China (973 program)

CAMS Initiative for Innovative Medicine

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 155 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancer demethylation-regulated gene score identified molecular subtypes, inspiring immunotherapy or CDK4/6 inhibitor therapy in oesophageal squamous cell carcinoma;eBioMedicine;2024-07

2. Comparison of the efficacy and safety of domestically produced tislelizumab, camrelizumab, and imported pembrolizumab in the treatment of advanced NSCLC: a real-world retrospective study;Clinical and Translational Oncology;2024-06-27

3. Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strategies and future directions;Expert Review of Clinical Immunology;2024-06-17

4. A machine learning radiomics based on enhanced computed tomography to predict neoadjuvant immunotherapy for resectable esophageal squamous cell carcinoma;Frontiers in Immunology;2024-06-14

5. Camrelizumab, chemotherapy and apatinib in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trial;eClinicalMedicine;2024-05